business / news / / The Sunday Times
Danish pharmaceutical giant Novo Nordisk is an object lesson in the risks inherent when investing in highly rated growth companies.
Novo Nordisk announced 9,000 layoffs in late 2023, the largest in its history.
KEY POINTS
- Denmark's economic growth outlook was halved due to Novo Nordisk's decline.
- Wegovy's US price will be cut to around a third of current levels after 2023 negotiations.
- Novo Nordisk's late-stage CagriSema trials showed inferior effectiveness compared to Eli Lilly's rival drug.
- The Novo Nordisk board was overhauled in late 2023, with seven changes and a new CEO appointed.
COMPANIES
Summarized by Newsio from The Sunday Times. How we summarize →